A MERS-CoV-like mink coronavirus uses ACE2 as an entry receptor

Ningning Wang1, Weiwei Ji2, Houqi Jiao1,3

  • 1Academy for Advanced Interdisciplinary Studies, College of Veterinary Medicine, Engineering Laboratory of Animal Immunity of Jiangsu Province, Nanjing Agricultural University, Nanjing, China.

Nature
|April 30, 2025
PubMed

Insights

A novel mink respiratory coronavirus (MRCoV) can infect multiple species, including humans, by binding to the ACE2 receptor. This discovery highlights fur farms as potential reservoirs for zoonotic viruses and emphasizes the need for increased surveillance.

Area of Science:

  • Virology
  • Zoonotic Diseases
  • Molecular Biology

Background:

  • Bat coronaviruses often require intermediate hosts for human transmission.
  • The role of fur animals in zoonotic coronavirus spillovers is understudied.

Purpose of the Study:

  • To isolate and characterize a novel coronavirus from farmed minks.
  • To investigate the zoonotic potential of this mink-derived coronavirus.

Main Methods:

  • Isolation and characterization of a novel mink respiratory coronavirus (MRCoV).
  • Analysis of MRCoV's interaction with angiotensin-converting enzyme 2 (ACE2) using cryo-electron microscopy.
  • Assessment of MRCoV's infectivity in various cell types (mink, bat, monkey, human).
  • Evaluation of therapeutic strategies using SARS-CoV-2 inhibitors.

Main Results:

  • A novel MRCoV was isolated from farmed minks with pneumonia.
  • MRCoV utilizes ACE2 as an entry receptor and infects multiple species' cells.
  • MRCoV's receptor-binding domain (RBD) binds to the same ACE2 interface as SARS-CoV-2 RBD.
  • A related bat coronavirus adapted to mink ACE2 with two amino acid substitutions.
  • SARS-CoV-2 protease and polymerase inhibitors effectively blocked MRCoV infection.

Conclusions:

  • MRCoV possesses significant zoonotic potential due to its ACE2 binding and cross-species infectivity.
  • Fur farms may serve as reservoirs for emerging coronaviruses, necessitating enhanced surveillance.
  • Antiviral inhibitors targeting SARS-CoV-2 show promise for treating MRCoV infections.